Taking part in a clinical trial can be a good choice but it is often hard to find a clinical trial that is right for you. Many patient organisations and websites maintain lists of clinical trials. The following tables list some of the many clinical trials available worldwide and focus primarily on immuno-oncology trials for kidney cancer patients. Please note: this is not an exhaustive list, so please check with your local patient organisation. Other trials may be available in your country. If you are aware of an open trial that should be listed here, please send us the trial information to: This email address is being protected from spambots. You need JavaScript enabled to view it.
For more information about understanding and finding trials, click here.
Trial name | Agents | Phase | Status | Sponsor | Further information |
ADAPTeR | Nivolumab pre and post-OP | II |
Open,
recruiting
|
Royal Marsden | click here |
Pembrolizumab-031 | Pembrolizumab (MK-3475) | I |
Open,
recruiting
|
Merck Sharp
& Dohme Corp.
|
click here |
PROSPER | Nivolumab | III | Open, recruiting |
Dana Faber
Cancer Institute
|
click here |
Trial name | Agents | Phase | Status | Sponsor | Further information |
IMmotion010 | Atezolizumab | III |
Open,
recruiting
|
Hoffmann-La Roche | click here |
Checkmate 914 | Nivolumab + Ipilimumab | III | Open, recruiting | Bristol-Myers Squibb | click here |
Keynote 564 | Pembrolizumab | III | Open, recruiting | Merck Sharp & Dohme Corp. | click here |
PROSPER | Nivolumab | III |
Open,
recruiting
|
Dana Faber Cancer Institute | click here |
RAMPART |
Durvalumab and
tremelimumab
|
III |
Open,
recruiting
|
University College,
London,
AstraZeneca
|
click here |
Trial name | Agents | Phase | Status | Sponsor | Further information |
Checkmate 214 |
Nivolumab+ipilimumab
versus sunitinib
|
III | Closed to accrual | Bristol-Myers Squibb | click here |
ADAPT |
AGS-003 versus
sunitinib
|
III | Ongoing, not recruiting | Argos Therapeutics | click here |
Atezolizumab (MPDL3280 A) + bevacizumab versus
sunitinib
|
III |
Ongoing,
not
recruiting
|
Hoffmann-La Roche | click here | |
Javelin Renal 101 | Avelumab + axitinib | III |
Ongoing,
not
recruiting
|
Pfizer | click here |
Nivolumab vs. nivolumab+bevacizumab vs. nivolumab + ipilimumab | II |
Ongoing, not recruiting
|
MD Anderson | click here | |
interferon alpha 2a
|
I/II | Completed | Spanish Oncology Genito-Urinary Group Novartis |
click here | |
Pembrolizumab + bevacizumab |
Pembrolizumab +
bevacizumab
|
I/II |
Ongoing, not recruiting
|
Merck Sharp & Dohme Corp. | click here |
Atezolizumab +
interferon alpha 2b
|
I |
Ongoing, not
recruiting
|
Hoffman-La Roche | click here | |
Pembrolizumab + pazopanib |
Pembrolizumab +
pazopanib
|
I | Ongoing, not recruiting |
Novartis,
Merck Sharp
& Dohme Corp. |
click here |
Pembrolizumab + axitinb |
Pembrolizumab +
axitinb
|
I | Ongoing, not recruiting | Pfizer | click here |
Javelin renal 100 | Avelumab + axitinib | I | Open, recruiting | Pfizer | click here |
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab vs. Sunitinib | Lenvatinib, everolimus, pembrolizumab, sunitinib | III | Open, recruiting |
Eisai Inc. |
|
KEYNOTE-426 | Pembolizumab + axitinib vs. sunitinib | III |
Ongoing,
not recruiting
|
Merck Sharp & Dohme Corp. | click here |
CheckMate 800 | Nivolumab plus ipilimumab | II |
Open,
recruiting
|
Bristol-Myers Squibb | click here |
KEYNOTE-427 | Pembrolizumab | II |
Ongoing,
not
recruiting
|
Merck Sharp & Dohme Corp. | click here |
FRACTION-RCC | Nivolumab + ipilimumab vs. Nivolumab + BMS-986016 | II | Open, recruiting | Bristol-Myers Squibb | click here |
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery | Pazopanib hydrochloride | III |
Ongoing, not
recruiting
|
National Cancer Institute (NCI) | click here Patient-friendly review will be available soon |
Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma | Atezolizumab + bevacizumab | II | Open, recruiting | Dana-Farber Cancer Institute | click here |
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma | AGS-16C3F vs. axitinib | II | Open, recruiting | Agensys, Inc. | click here |
S1500 - Cabozantinib, Crizotinib, Volitinib, or Sunitinib in Treating Patients With Locally Advanced or Metastatic Papillary Kidney Cancer | Cabozantinib, crizotinib, volitinib, sunitinib | II |
Open,
recruiting
|
National Cancer Institute (NCI) | click here |
Savoir | Savolitinib, sunitinib | III | Open, recruiting | AstraZeneca | click here |
Checkmate 920 | Nivolumab, ipilimumab | IV |
Open,
recruiting
|
Bristol-Myers Squibb | click here |
Checkmate 9ER | Nivolumab, cabozantinib, sunitinib | III |
Open,
recruiting
|
Bristol-Myers Squibb | click here |
UNISoN | Nivolumab, Ipilimumab | II |
Open,
recruiting
|
ANZUP | click here |
Trial name | Agents | Phase | Status | Sponsor | Further information |
Checkmate 025 | Nivolumab versus everolimus | III | Stopped, results published at the ECC 2015 | Bristol-Myers Squibb | click here |
Nivolumab vs. nivolumab+bevacizumab vs. nivolumab + ipilimumab | II |
Ongoing,
not recruiting
|
MD Anderson | click here | |
Pembrolizumab + interferon alpha 2b +
ipilimumab
|
I/II | Open, recruiting | Merck Sharp & Dohme Corp. | click here | |
Pazopanib +
interferon alpha 2a
|
I/II | Completed | Spanish Oncology Genito-Urinary Group Novartis |
click here | |
Pembrolizumab + bevacizumab |
Pembrolizumab +
bevacizumab
|
I/II |
Ongoing, not recruiting
|
Merck Sharp & Dohme Corp. | click here |
Atezolizumab +
interferon alpha 2b
|
I |
Ongoing,
not
recruiting
|
Hoffman-La Roche | click here | |
Cabozantinib plus nivolumab against cabozantinib + nivolumab + ipilimumab | Cabozantinib + nivolumab + ipilimumab | I |
Open,
recruiting
|
National Cancer Institute (NCI)/ Exelixis | click here |
X4P-001 in Patients With Advanced Renal Cell Carcinoma | X4P-001 + axitinib | I/II | Open, recruiting | X4 Pharmaceuticals | click here |
Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) | Pembrolizumab (MK-3475) + Epacadostat (INCB024360) | I/II | Closed for kidney cancer patients | Incyte Corporation, Merck Sharp & Dohme Corp. |
click here |
Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumours | Lenvatinib + pembrolizumab | Ib/II | Open recruiting | Eisai Inc. | click here |
Checkmate 800 | Nivolumab +ipilimumab | II | Open, recruiting | Bristol-Myers Squibb | click here |
FRACTION-RCC | Nivolumab + ipilimumab vs. Nivolumab + BMS-986016 | II | Open, recruiting |
Bristol-Myers Squibb | click here |
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma | AGS-16C3F vs. axitinib | II | Open, recruiting | Agensys, Inc. | click here |
S1500 - Cabozantinib, Crizotinib, Volitinib, or Sunitinib in Treating Patients With Locally Advanced or Metastatic Papillary Kidney Cancer | Cabozantinib, crizotinib, volitinib, sunitinib | II |
Open,
Recruiting
|
National Cancer Institute (NCI) | click here |
Savoir | Savolitinib, sunitinib | III | Open, recruiting | AstraZeneca | click here |
UNISoN | Nivolumab, Ipilimumab | II |
Open,
recruiting
|
ANZUP | click here |
Trial name | Agents | Phase | Status | Sponsor | Further information |
Checkmate 025 | Nivolumab versus everolimus | III | Stopped, results published at the ECC 2015 | Bristol-Myers Squibb | click here |
Nivolumab vs. nivolumab+bevacizumab vs. nivolumab + ipilimumab | II |
Ongoing,
not recruiting
|
MD Anderson | click here | |
Pazopanib +
interferon alpha 2a
|
I/II | Completed | Spanish Oncology Genito-Urinary Group Novartis |
click here | |
Pembrolizumab + bevacizumab |
Pembrolizumab +
bevacizumab
|
I/II |
Ongoing, not recruiting
|
Merck Sharp & Dohme Corp. | click here |
Atezolizumab +
interferon alpha 2b
|
I |
Ongoing,
not
recruiting
|
Hoffman-La Roche | click here | |
Cabozantinib plus nivolumab against cabozantinib + nivolumab + ipilimumab | Cabozantinib + nivolumab + ipilimumab | I |
Open,
recruiting
|
National Cancer Institute (NCI)/ Exelixis | click here |
X4P-001 in Patients With Advanced Renal Cell Carcinoma | X4P-001 + axitinib | I/II | Open, recruiting | X4 Pharmaceuticals | click here |
Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) | Pembrolizumab (MK-3475) + epacadostat (INCB024360) | I/II | Closed for kidney cancer patients | Incyte Corporation, Merck Sharp & Dohme Corp. |
click here |
Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumours | Lenvatinib + Pembrolizumab | Ib/II |
Open,
recruiting
|
Eisai Inc. | click here |
Checkmate 800 | Nivolumab + ipilimumab | II |
Open,
recruiting
|
Bristol-Myers Squibb | click here |
Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC | Tivozanib Hydrochloride vs. sorafenib | III |
Ongoing,
not
recruiting
|
AVEO Pharmaceuticals, Inc. | click here |
FRACTION-RCC | Nivolumab + ipilimumab vs. Nivolumab + BMS-986016 | II | Open, recruiting |
Bristol-Myers Squibb | click here |
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma | AGS-16C3F vs. axitinib | II | Open, recruiting | Agensys, Inc. | click here |
Savoir | Savolitinib, sunitinib | III | Open, recruiting | AstraZeneca | click here |
UNISoN | Nivolumab, Ipilimumab | II |
Open,
recruiting
|
ANZUP | click here |